<DOC>
	<DOCNO>NCT01261286</DOCNO>
	<brief_summary>Objective : To determine effect C-reactive protein ( CRP ) status , infliximab treatment pharmacodynamics pharmacokinetics verapamil , model drug L-type calcium channel blocking , Crohn 's disease ( CD ) patient compare healthy patient . Hypotheses : CD patient elevate plasma verapamil concentration , diminish dromotropic response verapamil ; concentration circulate norepinephrine , use surrogate marker sympathetic nervous activity , similar healthy patient CD patient ; sympathetic nervous system heart similar healthy patient ; Crohn 's disease patient normal CRP high drug response compare high CRP ( &gt; 3 mg/l ) patient ; infliximab-treated patient higher verapamil response similar symptom profile infliximab treat .</brief_summary>
	<brief_title>Drug-Disease Interaction Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Willingness adhere study protocol Males female nonchildbearing potential age 18 65 year Lab value 10 % outside lab 's state normal range unless subject Crohn 's disease group value relate disease , PI decide abnormality clinically significant The subject healthy ( except Crohn 's disease group ) Nonsmoker least 3 month History hypersensitivity verapamil Significant history gastrointestinal ( Crohn 's disease ) , liver , kidney , disease condition know interfere absorption , distribution , metabolism excretion drug Significant history allergy Significant history cardiovascular hematological disease Significant history asthma , chronic bronchitis bronchospastic condition Presence diabetes mellitus condition would preclude fasting Maintenance therapy drug ( except prescribe Crohn 's disease ) history drug dependence , alcohol abuse , serious psychological disease Any clinically significant illness Crohn 's disease previous 30 day prior study Use enzymemodifying drug previous 30 day study Blood donation previous 56 day multiple blood sampling previous 30 day study History faint upon blood sample Participation another clinical trial within 30 day study Narcotic use Glucocorticoid treatment last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>inflammation</keyword>
	<keyword>receptor downregulation</keyword>
	<keyword>reduce response</keyword>
	<keyword>calcium channel</keyword>
	<keyword>PK-PD relationship</keyword>
</DOC>